| Name | Title | Contact Details |
|---|
Kee Safety, Inc. is one of the worlds leading Safety Solutions Suppliers. We have been providing industry specific solutions such as railings, barriers, perimeter protection, fall prevention and many other applications since 1934. From Machine Guards to Roof Edge Fall Protection, Guardrailing to Pedestrian Barriers, Shop Fitting to Childrens Playgrounds, Kee Safety has supplied the answer to many problems with safe, reliable, cost effective and durable solutions. Please visit our website for more information.
Welcome to Hollywood Chrysler Jeep! Here at Hollywood Chrysler Jeep, we pride ourselves on taking a different approach to selling vehicles by getting to know each and every one of our customers so we can provide a comfortable and unique shopping atmosphere. To us, its about so much more than just making the sale, because we know how important getting a fair deal on quality transportation really is for you!
AcquireTek Is on its way back in 2025 with a new exciting M&A offering! Stay tuned!!!
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.